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Evaluating Estradiol as a Novel Therapy for Dry Agerelated Macular Degeneration/Geographic Atrophy
Daniel H Lee, Paula S Fukuhara, MC Kenney
PURPOSE:
Age-related macular degeneration (AMD) is
the most common cause of irreversible
vision loss in the elderly population in the
United States and is more prevalent in postmenopausal females than age-matched
males. There are no current FDA-approved
therapies for dry AMD, which composes 8090% of all AMD cases. Late stage dry AMD
(geographic atrophy) is characterized by
extensive loss of the retinal pigment
epithelium (RPE) along with degeneration
of the photoreceptors, which cause
significant central vision loss. AMD is
characterized by drusen, which are
extracellular deposits located beneath the
retina. Drusen contain proteins associated
with the process of inflammation such as
activated complement proteins, fragments of
the membrane attack complex, vitronectin,
cholesterol, C-reactive protein, and amyloidβ. Amyloid-β is a cytotoxic protein
associated with various neurodegenerative

diseases and is commonly found in plaques
of Alzheimer’s disease.
Based on these findings, we hypothesized
that estradiol may have protective effects
against the cytotoxic properties of amyloid-b
in RPE cells in vitro.
METHODS:
ARPE-19 cells were pretreated with 17-β
estradiol 20-160 nM for 6 h and then
stressed with 5 μM active amyloid-β1-42 for
24 h. Scrambled amyloid-β42-1 and
equivalent volume DMSO solutions were
used as negative controls. Cell viability
(MTT Assay), reactive oxygen species
(ROS) production (H2DCFDA Assay), and
mitochondrial membrane potential (JC-1
Assay) were assessed. Statistical analysis
was performed by GraphPad Prism software.
Statistical significance was determined at
P42-1.
RESULTS:
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ARPE-19 cells stressed with 5 μM amyloidβ1-42 had a significant decrease in cell
viability (P = 0.0007), which was not
reversed by pretreatment with 20 and 40 nM
estradiol. The 5 μM active amyloid-β1-42 did
not alter the levels of ROS or mitochondrial
membrane potential compared to the
scrambled amyloid-b42-1. In addition,
pretreatment with 20-160 nM estradiol did
not significantly decrease ROS production
or increase mitochondrial membrane
potential in amyloid-b1-42 treated cultures.
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CONCLUSION: Amyloid-β1-42 decreases
ARPE-19 cell viability but not through
mechanisms of ROS production or by
affecting the mitochondrial membrane
potential. Although estradiol has been
shown to be protective on the retina when
stressed with light or high glucose-induced
damage, our findings demonstrate that with
amyloid-β1-42-induced damage, the estradiol
was unable to prevent RPE death
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